A3 receptor ligands: Past, present and future trends

Current Topics in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 942-975

  Taliani, S ^a   Pugliesi, I ^a   Bellandi, M ^a   la Motta, C ^a   da Settimo, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

A3 AR ligands; Adenosine receptor (AR); AR subtype selectivity; Binding affinity; Structure activity relationships

Indexed keywords

1 DEOXY 1 [6 [[[(4 SULFONAMIDOPHENYL)AMINO]CARBONYL]AMINO] 9H PURIN 9 YL] N ETHYL BETA DEXTRO RIBOFURANURONAMIDE; 2 (4 METHOXYPHENYL) 1,2,4 TRIAZOLO[1,5 A]QUINOXALIN 4 ONE; 8 CHLORO 2 PHENYL 1,2,4 TRIAZOLO[1,5 A]QUINOXALIN 4 AMINE; 9 (5 ETHYLCARBAMOYL BETA DEXTRO RIBOFURANOSYL) N6 METHYL 2 (4 PYRIDIN 2 YL 1,2,3 TRIAZOL 1 YL)ADENINE; 9 CHLORO 5 (4 METHOXYBENZOYL)AMINO 2 PHENYL[1,2,3]TRIAZOLO[1,2 A][1,2,4]BENZOTRIAZIN 1 ONE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR; ALKYNYL GROUP; G PROTEIN COUPLED RECEPTOR; LIGAND; LJ 529; MRS 1898; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG; ZR 1121 9; NUCLEOSIDE;

ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; HEART MUSCLE ISCHEMIA; IMMUNE DEFICIENCY; INFLAMMATION; INTRAOCULAR PRESSURE; MULTIGENE FAMILY; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; ANIMAL; BINDING SITE; CHEMISTRY; HUMAN; REVIEW;

ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; BINDING SITES; HUMANS; LIGANDS; NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953486951     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791293109     Document Type: Article

References (113)

1. Meyerhof, W.; Muller-Brechlin, R.; Richter, D. Molecular cloningof a novel putative G-protein coupled receptor expressed during ratspermiogenesis. FEBS Lett., 1991, 284, 155-160.
2. Poulsen, S.-A.; Quinn, R. J. Adenosine receptors: newopportunities for future drugs. Bioorg. Med. Chem., 1998, 6, 619-641.
3. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, 362,364-374.
4. Fredholm, B. B.; IJzerman A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV.Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527-552.
5. 3 Receptor Subtype. Curr. Top. Med. Chem.,2003, 3, 463-469.
6. Schulte, G.; Fredholm, B. B. Signalling from adenosine receptorsto mitogen-activated protein kinases. Cell. Signal, 2003, 15, 813-827.
7. 1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J., 2004, 18,406-408.
8. Schulte, G.; Fredholm, B. B. Signaling pathway from the humanadenosine A(3) receptor expressed in Chinese hamster ovary cellsto the extracellular signal-regulated kinase 1/2. Mol. Pharmacol.,2002, 58, 1137-1146.
9. 3 adenosine receptor withwidespread tissue distribution. Mol. Pharmacol., 1993, 44, 524-532.
10. 3 receptors: Pharmacologicalproperties, species differences and receptor functions. Trends Pharmacol. Sci., 1994, 15, 298-306.
11. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci.USA, 1998, 95, 6995-6999.
12. 3 adenosine receptor-mediated protectionof the ischemic heart. Vascul. Pharmacol., 2005, 42, 271-279.
13. Akkari, R.; Burbiel, J. C.; Hockemeyer, J.; Müller, C. E. Recentprogress in the development of adenosine receptor ligands asantiinflammatory drugs. Curr. Top. Med. Chem., 2006, 6, 1375-1399.
14. - channels of nonpigmented ciliary epithelialcells. Am. J. Physiol., 1999, 276, 659-666.
15. 3 adenosine receptor affectscell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol., 2000, 361, 225-234.
16. 3 adenosine receptors in human tumor cell lines. Curr. Med.Chem., 2005, 12, 1319-1329.
17. 3 adenosine receptors in human Colorectal cancer isreflected in peripheral blood cells. Clin. Cancer Res., 2004, 10,5895-5901.
18. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutictargets. Nat. Rev. Drug Discov., 2006, 5, 247-264.
19. Moro, S.; Gao, Z.-G.; Jacobson, K. A.; Spalluto, G. Progress in thepursuit of therapeutic adenosine receptor antagonists. Med. Res.Rev., 2006, 26, 131-159.
20. 3 receptorligands. Curr. Top. Med. Chem., 2003, 3, 445-462.
21. 3 adenosinereceptor: agonists, antagonists, and receptor engineering. Handb.Exp. Pharmacol., 2009, 193, 123-159.
22. 3 adenosine receptors. Curr. Top. Med. Chem., 2005, 5, 1275-1295.
23. 3 adenosine receptor: an enigmatic player in cellbiology. Pharmacol. Ther., 2008, 117, 123-140.
24. 3 Adenosine subtype. J.Cell. Physiol., 2007, 211, 826-836.
25. 3 Adenosine receptoractivation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent Inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanomacells. J. Biol. Chem., 2005, 280, 19516-19526.
26. 6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methyl carboxamide]protects against myocardial ischemia/reperfusion injury via thesarcolemmal ATP-sensitive potassium channel. J. Pharmacol. Exp.Ther., 2008, 324, 234-243.
27. 3R as a therapeutic target in experimental colitis: proof by validatedhigh-density oligonucleotide microarray analysis. Inflamm. BowelDis., 2006, 12, 766-789.
28. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Merighi S.; Varani, K.; Borea, P. G.; Spalluto, G. A(3) adenosine receptor ligands: historyand perspectives. Med. Res. Rev., 2000, 20, 103-128.
29. 3 adenosine receptor activation: Nucleoside ligands at theagonist/antagonist boundary. J. Med. Chem., 2002, 45, 4471-4484.
30. 3-selectiveadenosine agonists. J. Med. Chem., 1994, 37, 636-646.
31. 3 adenosine receptors. Biochem.Pharmacol., 2003, 65, 1675-1684.
32. 3 adenosine receptors. J.Med. Chem., 1994, 37, 3614-3621.
33. 2 adenosine receptors.J. Med. Chem., 1992, 35, 2363-2368.
34. 2 adenosine receptor agonists with potent inhibitoryactivity on platelet aggregation. J. Med. Chem., 1994, 37, 1720-1726.
35. 2A adenosine receptor agonists. J. Med. Chem., 1995,38, 1462-1472.
36. 3 Receptor Ligandsrecombinant adenosine receptors. Drug Dev. Res., 1998, 45, 176-181.
37. Volpini, R.; Costanzi, S.; Lambertucci, C.; Vittori, S.; Cristalli, G.Purine nucleosides bearing 1-alkynyl chains as adenosine receptoragonists. Curr. Pharm. Des., 2002, 8, 2285-2298.
38. 3 adenosine receptor ligands.Nucleosides, Nucleotides Nucleic Acids, 2005, 24, 935-938.
39. 2B ligands. J. Med. Chem., 2002, 45,3271-3279.
40. 3 adenosine receptoragonists. J. Med. Chem., 1998, 41, 3174-3185.
41. Volpini, R.; Camaioni, E.; Costanzi, S.; Vittori, S.; Klotz, K.-N.; Cristalli, G. Synthesis of di- and tri-substituted adenosinederivatives and their affinity at human adenosine receptorsubtypes. Nucleosides Nucleotides, 1999, 18, 2511-2520.
42. 3 selectiveligands containing bioisosteric isoxazoles. Bioorg. Med. Chem.Lett., 1998, 8, 1676-1770.
43. 3 receptor. J. Med. Chem., 2007, 50, 1222-1230.
44. Klotz, K.-N.; Hessling, J.; Hegler, Owman, B.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparartive pharmacology of humanadenosine subtypes-characterization of stably transfected receptorsin CHO cells. Naunyn-Schiemedeberg's Arch. Pharmacol., 1998,337, 1-7.
45. 3 receptor. J. Med. Chem., 2009,52, 7897-7900.
46. 3 adenosine receptor agonists.Bioorg. Med. Chem. Lett., 2006, 16, 2416-2418.
47. 3 receptor agonists. J. Med. Chem., 2004, 47,4766-4773.
48. 3 adenosine receptoragonists, partial agonists, and antagonists. J. Med. Chem., 2006,49, 7373-7383.
49. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radic, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. Click chemistry insitu: acetylcholinesterase as a reaction vessel for the selectiveassembly of a fentomolar inhibitor from an array of buildingblocks. Angew. Chem. Int. Ed., 2002, 41, 1053-1057.
50. Ohno, M.; Gao, Z.-G.; Van Rompaey, P.; Tchilibon, S.; Kim, S.-K.; Harris, B. A.; Gross, A. S.; Duong, H. T.; Van Calenberghb, S.; Jacobson, K. A. Modulation of adenosine receptor affinity andintrinsic efficacy in adenine nucleosides substituted at the 2-position. Bioorg. Med. Chem., 2004, 12, 2995-3007.
51. 3 adenosine receptors. J. Med. Chem., 1996,39, 802-806.
52. 3 adenosine receptor agonists. J. Med. Chem., 2004, 47, 5535-5540
53. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg.Med. Chem., 2004, 12, 2021-2034.
54. 3 receptor ligands. Bioorg. Med. Chem.Lett., 2003, 13, 817-820.
55. 3 adenosine receptoragonists. Nucleosides Nucleotides Nucleic Acids, 2008, 27, 408-420.
56. 3 receptor. J. Med.Chem., 2003, 46, 353-355.
57. 3 adenosine receptor. Bioorg. Med. Chem. Lett.,2004, 14, 4851-4854.
58. 3adenosine receptor. J. Med. Chem., 2003, 46, 3775-3777.
59. 3adenosine receptor. J. Med. Chem. 2006, 49, 273-281.
60. 3 adenosine receptor. J. Biol. Chem., 2002, 277, 19056-19063.
61. 3 adenosine receptor. Bioorg. Med. Chem., 2006, 14,4718-4730.
62. Jacobson, K. A.; Ji, X.-D.; Li, A.-H.; Melman, N.; Siddiqui, M. A.; Shin, K.-J.; Marquez, V. E.; Ravi, R. G. Methanocarba analoguesof purine nucleosides as potent and selective adenosine receptoragonists. J. Med. Chem., 2000, 43, 2196-2203.
63. Lee, K.; Ravi, R. G.; Ji, X.-D.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (N)methanocarba-nucleosides as adenosinereceptor agonists: Independent 5'-uronamide and 2'-deoxymodifications, Bioorg. Med. Chem. Lett., 2001, 11, 1333-1337.
64. 3 adenosinereceptor agonists. J. Med. Chem., 2005, 48, 1745-1758.
65. 3 adenosine receptor antagonists derived fromnucleosides containing a bycyclo[3.1.0]hexane ring system.Bioorg. Med. Chem., 2008, 16, 8546-8556.
66. 3 receptor can explain their different biologicalbehavior. J. Mol. Graph. Model., 2003, 21, 253-262.
67. 3 receptor. Bioorg. Med. Chem. Lett., 2006, 16, 2525-2527.
68. 3 adenosine receptor. J. Mol. Graph. Model., 2006, 25,562-577.
69. 3adenosine receptor agonists into selective antagonists bymodification of the 5'-ribofuran-uronamide moiety. Bioorg. Med. Chem. Lett., 2006, 16, 596-601.
70. 3 adenosine receptor antagonists. Bioorg. Med. Chem. Lett., 2008,18, 1612-1616.
71. 3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group ashighly potent and selective antagonists. J. Med. Chem., 2007, 50,3159-3162.
72. 3adenosine receptor antagonists. J. Med. Chem., 2008, 51, 6609-6613.
73. 3 adenosine receptorantagonists. Bioorg. Med. Chem., 2009, 17, 3733-3738.
74. 3 receptor ligands. Bioorg.Med. Chem., 2006, 14, 1403-1412.
75. 3 receptor ligands. Bioorg. Med. Chem., 2007, 15,5440-5447.
76. 3 adenosine receptor ligands, 2'-fluoro analoguesof Cl-IB-MECA. Nucleosides Nucleotides Nucleic Acids, 2003, 22,927-930.
77. Priego, E. M.; von Frijtag Drabbe Kunzel, J. K.; Ijzerman, A. P.; Camarasa, M. J.; Perez-perez, M.-J. Pyrido[2,1-f]purine-2,4-dionederivatives as a novel class of highly potent human A(3) adenosinereceptor antagonists. J. Med. Chem., 2002, 45, 3337-3344.
78. 3 antagonistbinding. ChemMedChem, 2008, 3, 111-119.
79. 3adenosine receptor antagonists. J. Med. Chem., 2005, 48, 4697-4701.
80. 3 adenosine receptor antagonists. Bioorg.Med. Chem., 2008, 16, 10281-10294
81. 3 receptor antagonists. An approach to theoptimization of protein models. J. Med. Chem., 2006, 49, 4085-4097.
82. 2A adenosine receptor antagonists. J. Med. Chem., 1998,41, 2126-2133.
83. 2A adenosinereceptor antagonists. Farmaco, 1996, 51, 297-300.
84. 2a receptors. Arzneimittelforschung,1996, 46, 365-368.
85. Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Pineda de Las Infantas y Villatoro, M. J.; Zocchi, C.; Dionisotti, S.; Ongini, E. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potentand selective A(2A) adenosine antagonists. J. Med. Chem., 1996,39, 1164-1171.
86. 3adenosine receptor antagonists: pirazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem., 2005, 48,152-162.
87. 3 adenosine receptor antagonist. J. Med. Chem.,2002, 45, 3579-3582.
88. 3 adenosine receptor antagonists.Influence of the heteroaryl substituent on binding affinity andmolecular modeling investigations. J. Med. Chem., 2006, 49, 1720-1729.
89. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Capitani, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. Pyrazolo-triazolopyrimidine derivatives sensitive melanoma cells to thechemiotherapic drugs: taxol and vindesine. Biochem. Pharmacol.,2003, 66, 739-748.
90. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. 1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent andselective adenosine receptor antagonists. J. Med. Chem., 2000, 43,1158-1164.
91. Colotta, V.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activityrelationships of a new set of 1,2,4-Triazolo[4,3-a]quinoxalin-1-onederivatives as adenosine receptor anatgonists. Bioorg. Med. Chem.,2003, 11, 3541-3550.
92. 3 adenosinereceptor anatgonists: synthesis, pharmacological and ligand-receptor modeling studies. J. Med. Chem., 2004, 47, 3580-3590.
93. 3adenosine receptor antagonists. Synthesis, pharmacologicalevaluation, and ligand-receptor modeling studies. J. Med. Chem.,2006, 49, 3916-3925.
94. 3 adenosine receptor antagonists. Bioorg. Med. Chem., 2008, 16, 6086-6102.
95. 3 adenosine receptorantagonists. Snthesis, pharmacological evaluation, and ligand-receptor modeling studies. J. Med. Chem., 2009, 52, 2407-2419.
96. Moro, S.; Deflorian, F.; Bacilieri, M.; Spalluto, G. Ligand-basedhomology modeling as attractive tool to inspect GPCR structuralplasticity. Curr. Pharm. Des., 2006, 12, 2175-2185.
97. 3 adenosine receptor anatgonists. Bioorg. Med. Chem., 2005, 13, 705-715.
98. 3 adenosine receptor anatgonists: synthesis,biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. J. Med. Chem.,2005, 48, 7932-7945.
99. 3 adenosine receptor antagonists. J. Med. Chem., 2007,50, 5676-5684.
100. 3 adenosine receptor antagonists. Synthesis,pharmacological evaluation, and ligand-receptor modelling studies.J. Med. Chem., 2007, 50, 4061-4074.
101. 3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular dockinganalysis and pharmacological studies. Bioorg. Med. Chem., 2009,17, 401-410.
102. 3 adenosine receptor anatagonists. J. Med.Chem., 2005, 48, 5001-5008.
103. 2A binding activity. Eur.J. Med. Chem., 1995, 30, 133-139.
104. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J. Med.Chem., 2000, 43, 3118-3124.
105. Primofiore, G.; Da Settimo, F.; Taliani, S.; Salerno, S.; Novellino, E.; Greco, G.; Cosimelli, B.; Besnard, F.; Costa, B.; Montali, M.; Martini, C. High affinity central benzodiazepine receptor ligands:synthesis and biological evaluation of a series ofphenyltriazolobenzotriazindione derivatives (PTBTs). J. Med.Chem., 2005, 48, 2936-2943.
106. 3 adenosine receptor antagonist bindingmode using a molecular simplification approach: fromtriazoloquinoxaline to a pyrimidine skeleton as a key study. J.Med. Chem., 2007, 50, 6596-6606.
107. 3 adenosinereceptor antagonists: new insights into the receptor-antagonistrecognition. J. Med. Chem., 2009, 52, 7640-7652.
108. 3 adenosine receptors designed by 3D database searching. J. Med. Chem., 2005, 48, 8253-8260.
109. 3 adenosine receptor antagonists. J. Med.Chem., 2008, 51, 1764-1770.
110. 3anatagonists. Chem. Pharm. Bull., 2008, 56, 1126-1137.
111. 3 adenosine receptorantagonists. J. Med. Chem., 2000, 43, 4636-4646.
112. 3 adenosine receptorantagonists. Eur. J. Med. Chem., 2003, 38, 367-382.
113. 3 adenosinereceptor antagonists: synthesis, biochemical and molecularmodelling studies. Bioorg. Med. Chem., 2005, 13, 4679-4693.